Scientists created a special form of vitamin B12 that acts like a Trojan horse to attack cancer cells. The research shows this modified B12 (called nitrosylcobalamin) can sneak into cancer cells by using the same pathways that normal cells use to absorb B12. Once inside, it releases a toxic substance that kills the cancer cells while leaving healthy cells alone. This early laboratory study tested the approach on four different types of cancer cells and found it worked best on cancers that had high levels of specific B12 receptors. While these results are exciting, the research is still in early stages and hasn’t been tested in humans yet.
The Quick Take
- What they studied: Whether a modified form of vitamin B12 could specifically target and kill cancer cells by using the same entry points that cancer cells use to absorb regular B12
- Who participated: Four different types of human cancer cells grown in laboratory dishes (ovarian, breast, skin, and prostate cancer), not living patients
- Key finding: The modified B12 successfully killed cancer cells that had high levels of B12 receptors, and this effect was blocked when researchers prevented the B12 from entering cells or when they changed the acidity inside the cancer cells
- What it means for you: This is very early research that shows promise for a new type of cancer treatment, but it’s only been tested in lab dishes so far. Many years of additional testing in animals and humans would be needed before this could become a real treatment option. Do not consider this a current treatment option.
The Research Details
Researchers created a modified version of vitamin B12 that contains a toxic substance called nitric oxide. They tested this modified B12 on four different cancer cell lines grown in laboratory dishes. The scientists made some cancer cells produce extra amounts of a specific B12 receptor (a protein that acts like a door for B12 to enter cells). They then measured how well the modified B12 killed these cancer cells using standard laboratory tests. To understand how the modified B12 worked, they also blocked the B12 receptor with antibodies (immune proteins) and changed the acidity inside the cells to see if these changes stopped the modified B12 from working.
This research approach is important because it tests a new strategy for fighting cancer: using the cancer cell’s own nutrient-absorption system against it. Cancer cells often need more B12 than normal cells because they grow so quickly. By disguising a toxic substance as B12, researchers can potentially deliver poison directly to cancer cells while avoiding healthy cells. Understanding exactly how this works (through which doors it enters and where it acts inside the cell) helps scientists design better cancer treatments.
This is laboratory research using cancer cells grown in dishes, which is the earliest stage of drug development. The study was well-designed with appropriate controls (tests that check if the results are real), but results from cell cultures don’t always translate to living organisms. The research was published in a peer-reviewed scientific journal, meaning other experts reviewed it before publication. However, this work needs to progress through animal testing and eventually human clinical trials before it could become a real treatment.
What the Results Show
The modified B12 successfully killed cancer cells in all four cancer types tested. When researchers blocked the B12 receptor with antibodies, the cancer cells became resistant to the modified B12, showing that the cancer cells must use this specific receptor for the modified B12 to work. When cancer cells were made to produce extra B12 receptors, they became more sensitive to the modified B12 and died at lower doses. When researchers used chloroquine (a drug that changes the acidity inside cells) before adding the modified B12, the cancer cells survived, suggesting that the toxic substance needs to be released in a specific part of the cell (the lysosome) to kill the cancer.
The research showed a clear relationship between how many B12 receptors a cancer cell had and how sensitive it was to the modified B12. Cancer cells with more receptors died more easily. This suggests that the modified B12 would work best against cancers that naturally have high levels of B12 receptors. The study also confirmed that the modified B12 binds well to intrinsic factor, a protein that normally helps the body absorb B12, suggesting it mimics natural B12 closely enough to fool cancer cells.
This research builds on earlier studies showing that cancer cells need more B12 than normal cells. Previous research also showed that the modified B12 binds well to the proteins that transport B12. This new study adds important information by showing exactly how the modified B12 gets into cancer cells and where inside the cell it needs to act to be effective. The ‘Trojan horse’ strategy of disguising toxic substances as nutrients has been explored before, but this is a specific application using B12.
This study only tested cancer cells in laboratory dishes, not in living animals or humans. Results in dishes don’t always work the same way in living bodies. The study tested only four types of cancer cells, so it’s unclear if the approach would work for other cancer types. The research didn’t test whether the modified B12 would harm normal cells that also need B12. No information was provided about how long the modified B12 stays active in the body or how it would be delivered to tumors in a real patient. The study is very recent (2026) and hasn’t been independently verified by other research groups yet.
The Bottom Line
This research is too early to make any recommendations for patients. It’s laboratory research only and has not been tested in animals or humans. Anyone with cancer should continue following their doctor’s current treatment recommendations. This modified B12 approach may eventually become a treatment option, but that would require many years of additional research and testing. (Confidence level: This is preliminary research only.)
Cancer researchers and pharmaceutical companies should pay attention to this work as it suggests a promising new approach. Patients with cancer should be aware of this research direction but should not expect it to be available as a treatment soon. People interested in how scientists develop new cancer treatments may find this interesting as an example of early-stage drug development. This research should NOT influence current cancer treatment decisions.
If this research continues to show promise, the typical timeline would be: 2-3 years of additional laboratory testing, 3-5 years of animal testing, and then 5-10 years of human clinical trials before potential approval. This means any real treatment based on this research would likely be at least 10-15 years away, if it ever reaches patients at all.
Want to Apply This Research?
- Not applicable for current app users. This research is too early-stage to track. In the future, if clinical trials begin, users could track participation in research studies or monitor news about cancer treatment developments.
- No behavior changes are recommended based on this research. Users should continue following their doctor’s advice for cancer prevention (healthy diet, exercise, avoiding tobacco) and treatment recommendations.
- Users interested in this research direction should monitor scientific news sources and ClinicalTrials.gov for any future human studies involving this modified B12 approach. However, this is not something individuals need to actively track or monitor for personal health decisions at this time.
This research describes laboratory experiments with cancer cells in dishes and has NOT been tested in animals or humans. This is very early-stage research and should not be considered a current or near-future treatment option. If you have cancer or are at risk for cancer, please consult with your oncologist or healthcare provider about proven, evidence-based treatment options. Do not delay or change your current cancer treatment based on this research. This article is for educational purposes only and is not medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.